Myomo (NYSEAMERICAN:MYO) Director Joseph Jr. Manko Purchases 170,830 Shares

Posted by Geri Gentry on May 19th, 2026

Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) Director Joseph Jr. Manko acquired 170,830 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average cost of $0.86 per share, for a total transaction of $146,913.80. Following the completion of the transaction, the director directly owned 2,279,408 shares of the company’s stock, valued at approximately $1,960,290.88. This trade represents a 8.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Myomo Price Performance

Shares of MYO opened at $0.84 on Tuesday. The firm has a market capitalization of $32.42 million, a PE ratio of -2.33 and a beta of 1.39. The company’s 50-day moving average is $0.76 and its 200-day moving average is $0.84. Myomo, Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $3.45. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.73 and a quick ratio of 2.36.

Hedge Funds Weigh In On Myomo

Several institutional investors and hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP grew its stake in shares of Myomo by 62.8% in the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock valued at $65,000 after acquiring an additional 11,614 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Myomo by 93.6% in the third quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after acquiring an additional 14,705 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Myomo in the first quarter valued at about $75,000. Invesco Ltd. acquired a new position in shares of Myomo in the second quarter valued at about $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Myomo in the second quarter valued at about $38,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Craig Hallum reissued a “buy” rating on shares of Myomo in a research report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Myomo has a consensus rating of “Buy” and a consensus target price of $7.67.

Check Out Our Latest Report on MYO

Myomo Company Profile

(Get Free Report)

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.